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1. Introduction 
Although Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized 
by motor neuron death, recent studies now implicate the non-neuronal environment as a 
major contributor to motor neuron loss. This body of evidence has been amassed over the 
past 10-15 years and highlights glial cells as new therapeutic targets for ALS. Glial cells, 
once thought to be simply the “glue” of the central nervous system (CNS), are now realized 
to actively participate in neural transmission and serve complex roles in regulation of the 
CNS environment.  
Several glial cell types including astrocytes, microglia, and oligodendrocytes exist in the 
CNS; each serves a distinct function. Astrocytes comprise the majority of the CNS cellular 
space and act to regulate neurotransmitter concentrations at synapses, provide trophic 
support for neurons, and maintain metabolic and ionic homeostasis. Astrocytes can 
participate in the immune response, however, microglia serve as the resident immune cell of 
the CNS. Microglia are mobile, phagocytic, and constantly screening the CNS for possible 
infection or injury. Upon activation, microglia can secrete pro-inflammatory cytokines and 
chemokines to promote the clearance of any infectious agents and recruit other immune 
cells to the site of injury. Depending on the stimuli, microglia also are known to release 
neurotrophic growth factors and anti-inflammatory molecules to aid in repair and 
resolution of neural damage. Oligodendrocytes are the myelinating glia of the CNS which 
intimately interact with, and provide metabolic support to neurons. Oligodendrocytes are 
capable of producing myelin sheaths which insulate axons and aid in the conduction of 
action potentials. 
Ongoing research strives to define exactly how glial cells affect motor neuron survival in 
ALS. Furthermore, translation of these studies to the clinical setting begs for novel 
approaches to treat this new target for ALS.  
2. Non-neuronal cells contribute to motor neuron death in ALS 
The bulk of work on glial cells in ALS is derived from studies in rodent ALS models. The 
most widely used ALS models are rodents that ubiquitously express the human mutant 
superoxide dismutase 1 (SOD1) protein associated with dominantly-inherited familial ALS 
(fALS) (Gurney et al., 1994).  Currently, 12 different SOD1 mutations have been expressed in 
lines of transgenic mice leading to development of motor neuron disease.  By far, the most 
commonly used model is the SOD1 G93A mutant mouse which contains 25 copies of the 
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human SOD1 G93A transgene corresponding to a 10-15 fold increase in SOD1 protein (Chiu 
et al., 1995; Gurney et al., 1994). These mice develop a severe motor neuron disease which 
resembles many of the clinical and pathological features of human ALS. One of the first 
indications that non-neuronal cells were involved in disease came from studies where the 
mutant SOD1 gene was expressed only in neurons instead of ubiquitously.  Lines of 
transgenic mice were generated where mutant SOD1 expression was driven by either the 
Thy1 promoter or neurofilament light chain promoter (Jaarsma et al., 2008; Lino et al., 2002; 
Pramatarova et al., 2001). In two of these three studies (Lino et al., 2002; Pramatarova et al., 
2001), the mice did not develop any neurological disease phenotype leading to the 
hypothesis that mutant SOD1 must be expressed in multiple cell types to trigger ALS. A 
subsequent study did report motor neuron disease with neuronal mutant SOD1 expression, 
however, the disease onset was very late (~500 days of age) and highly variable, suggesting 
a possible contribution of mutant non-neuronal cells in disease (Jaarsma et al., 2008).  
Further studies combining various approaches continue to support this hypothesis (Clement 
et al., 2003; Miller et al., 2005). To evaluate the contribution of mutant SOD1 expression in 
different cell populations, chimeric mice were generated from a mixture of wild-type cells 
and cells that expressed mutant SOD1 (Clement et al., 2003). It was observed that mice with 
a greater proportion of wild-type cells to mutant SOD1 cells had extended survival. In 
addition, motor neurons expressing mutant SOD1 that were surrounded by wild-type non-
neuronal cells had less severe pathology. Likewise, wild-type motor neurons surrounded by 
non-neuronal cells expressing mutant SOD1 appeared to be degenerating, suggesting that 
neighboring non-neuronal cells may play a direct role in the death of MNs. To more directly 
discern the contribution of mutant SOD1 in motor neurons, transgenic mice were created 
where mutant SOD1 was removed by Hb9-driven cre recombinase solely in motor neurons. 
Although these mice have greatly reduced mutant SOD1 expression in motor neurons, they 
still develop motor neuron disease albeit a significant delay in disease onset (Boillee et al., 
2006a). Furthermore, targeting only the motor neurons with an siRNA to reduce mutant 
SOD1 levels showed only a transient effect of motor neuron protection, suggesting that 
other cell types were contributing to the ultimate demise of motor neurons (Miller et al., 
2005). Collectively, these studies suggest that ALS is a non-cell autonomous disease; non-
neuronal mutant SOD1-expressing cells can directly cause wild-type motor neurons to 
exhibit a disease phenotype. 
2.1 Astrocytes influence the course of disease in ALS 
Specific populations of glial cells have been analyzed to determine their precise role in 
motor neuron death in ALS. Astrocytes are glial cells with diverse roles including 
regulation of the extracellular CNS environment, maintenance of cell-cell communication, 
CNS vascular control, growth factor production, and neurotransmitter metabolism 
(Maragakis & Rothstein, 2006). Astrocytes can also become reactive and proliferative in 
response to neuronal death or CNS injury. Indeed, reactive astrocytosis and inflammation 
are prominent features in both the human ALS spinal cord as well as in rodent ALS 
models. Moreover, astrocytes have long been suspected to exacerbate motor neuron death 
due to their reported loss of glial glutamate transporter 1 (GLT1) [excitatory amino acid 
transporter 2 (EAAT2) in humans](Bendotti et al., 2001; Bristol & Rothstein, 1996; Bruijn et 
al., 1997; Rothstein et al., 1995). GLT1 is a glutamate transporter responsible for removing 
90% of the extrasynaptic glutamate to prevent continued neuronal firing.  Increased levels 
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of glutamate have been found in the cerebrospinal fluid of ALS patients (Rothstein et al., 
1990; Shaw et al., 1995). Chronic reduction in glutamate uptake results in a buildup of 
extracellular glutamate, leading to increased neuronal synaptic transmission and 
excitotoxic neuronal death. The ALS-linked GLT1 loss is found in both human ALS and in 
several rodent models and signifies astrocyte pathology as consistent theme in ALS 
pathobiology. However, it is difficult to discern whether astrocytes become dysfunctional 
due to motor neuron degeneration or whether dysfunction is a secondary event in the 
disease course.  
Recent studies aim to answer these questions by evaluating how mutant SOD1 expression 
in astrocytes affects disease course in the mutant SOD1 mouse model. In these sets of 
experiments, cre recombinase was driven using the GFAP promoter to excise the floxed 
mutant SOD1 gene solely in astrocytes. Depending on which SOD1 mutation was present, 
the reduction of mutant SOD1 in astrocytes either slows disease progression (SOD1 
G37R)(Yamanaka et al., 2008b) or slows disease onset and progression (SOD1 
G85R)(Wang et al., 2011).  Microgliosis was reduced and astrocytic GLT1 expression was 
maintained in one study (Wang et al., 2011), however, the exact mechanism for prolonged 
survival in these mice is still undefined. Nevertheless, it seems that the mutant SOD1 
protein directly causes astrocytes to become aberrant in the SOD1 mouse model and 
rescue of diseased astrocytes can significantly influence disease course.  It is also 
interesting to note that complete ablation of proliferating mutant SOD1 astrocytes in the 
SOD1 mouse model does not affect any measure of motor neuron disease in these mice. 
Therefore, astrocyte proliferation itself or the presence of mutant SOD1 in the 
proliferating astrocyte population does not seem to contribute to motor neuron 
degeneration (Lepore et al., 2008a).  
2.2 Microglia direct disease progression in ALS mouse models 
In addition to astrocytes, microglia are another important glial cell type in ALS pathogenesis 
due to their phagocytic properties and capacity to produce a wide array of cytokines and 
chemokines, attracting other cells to the site of injury. Indeed, extensive microglial activation 
and proliferation characterizes sites of motor neuron injury in human ALS and rodent 
models and this microgliosis increases as disease worsens (Henkel et al., 2009).  
Interestingly, investigations are ongoing as to whether microglia are neuroprotective, 
neurotoxic, or situationally both in ALS.  
To directly assess the role of mutant SOD1 in microglia of the SOD1 mouse model, two 
parallel studies sought to remove the mutant SOD1 G37R specifically from microglia in 
these transgenic mice.  In one study, the floxed mutant SOD1 gene was excised from 
microglia using cre recombinase driven by the Cd11b promoter, removing the gene from 
microglia and peripheral macrophages only (Boillee et al., 2006b). In the other parallel study, 
microglia were genetically ablated in the mutant SOD1 mouse followed by reconstitution 
with wild-type microglia through a bone-marrow transplant (Beers et al., 2006). The result 
from both studies was a slowed disease progression resulting in a dramatic extension in life 
in these mice. More recently, an additional study also showed slowed disease progression 
when a different SOD1 mutant, SOD1 G85R, was excised by cre recombinase solely in 
microglia (Wang et al., 2009). Collectively, these studies suggest the presence of mutant 
SOD1 in microglia causes these cells to adopt a more neurotoxic phenotype and directly 
affects motor neuron survival in the mutant SOD1 mouse model.  
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Other studies suggest that microglia may actually play a neuroprotective role in motor 
neuron disease. Evidence from other disease and injury models indicates that as 
microglia become activated, they can adopt either an “M1” proinflammatory phenotype 
or an “M2” alternatively activated phenotype leading to secretion of anti-inflammatory 
cytokines and neurotrophic factors (Henkel et al., 2009). Although mutant SOD1 
expression seems to cause microglia to lean toward proinflammatory M1 activation, 
microglia have also been shown to produce anti-inflammatory cytokines and 
neuroprotective growth factors during the early phase of disease in the ALS mice (Chiu 
et al., 2008).  Interestingly, several studies have indicated that T cells directly influence 
microglial activation and their differentiation toward a neuroprotective or 
proinflammatory phenotype. When SOD1 G93A mice were bred with a strain of mice 
lacking T cells, disease course was accelerated and this worsening of disease was 
accompanied by a decrease in alternative M2 microglial activation, although astrocytosis 
remained unchanged (Chiu et al., 2008). In addition, increased numbers of regulatory T 
cells are associated with the stable phase of disease in both mice and ALS patients and 
these regulatory T cells can promote microglia to adopt an anti-inflammatory M2 
phenotype (Beers et al., 2011). Over the course of disease, these regulatory T cells 
decrease in number accompanied by a shift in microglia from protective M2 to the 
proinflammatory M1 phenotype.  Therefore, this evidence suggests microglia adopt an 
activated neuroprotective M2 phenotype during early disease, but then develop into 
proinflammatory M1 microglia as disease progresses. Therapeutic approaches that 
promote M2 microglial differentiation or maintenance may prove to be an alternative to 
the limitation of microglial activation.  
2.3 The undefined role of oligodendrocytes and their progenitors in ALS 
While focus has been on the involvement of neurons, astrocytes and microglia in ALS 
pathogenesis, a few studies have investigated other glial cell lineages as well. In 
particular, myelinating oligodendrocytes of the central nervous system and Schwann 
cells of the peripheral nervous system form intimate connections with motor neurons 
and their axons, promote neuronal health through production of neurotrophic factors, 
and aid in regeneration after neuronal injury. Surprisingly little is known about the role 
of Schwann cells and oligodendrocytes in ALS, although pathological aberrations in 
myelin have been reported along peripheral nerves in human patients (Perrie et al., 
1993). As with glial inflammation, these myelin abnormalities may be primary or 
secondary to motor neuron degeneration. To specifically investigate whether mutant 
SOD1 alters Schwann cells, transgenic mice were created with SOD1 G93A expression 
restricted to myelinating Schwann cells using the myelin protein zero (P0) promoter 
(Turner et al., 2010). No evidence of motor neuron disease was observed in these mice, 
suggesting the mutant SOD1 protein is not detrimental to this Schwann cell population. 
In contrast, the specific removal of floxed mutant SOD1 in Schwann cells by P0-driven 
cre recombinase seems to modestly accelerate disease progression in the SOD1 G37R 
mice (Lobsiger et al., 2009). This curious disease acceleration is hypothesized to be a 
result of reducing SOD1’s normal dismutase activity in Schwann cells, which may serve 
an unrealized neuroprotective function during the nerve regeneration process. Thus, a 
clear role of mutant SOD1-expressing Schwann cells has not been determined in rodent 
ALS models.  
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Another open question in the field is whether oligodendrocytes and their NG2+ progenitor 
cells directly affect motor neuron loss in ALS. To date, only one study has investigated how 
mutant SOD1 in oligodendrocytes influences motor neuron loss and the experimental 
design causes the results to be difficult to interpret. In this study, chimeric mice were 
created by mixing embryonic cells expressing SOD1 G37R with wild-type cells lacking the 
Olig1 transcription factor (Yamanaka et al., 2008a). The Olig1 -/- mice are unable to form 
motor neurons or oligodendrocytes. Therefore, the motor neurons and oligodendrocytes in 
the chimeric mice were generated from the mutant SOD1 G37R cells which have normal 
Olig1 levels. The result is a chimeric mouse with mutant motor neurons and 
oligodendrocytes, but with all other cells being a mixture of mutant and wild-type cells. 
These mice did not develop the motor neuron disease typical in the SOD1 G37R mouse 
model and the authors suggest that mutant SOD1 expression in oligodendrocytes is not a 
significant contributor to motor neuron degeneration. However, technical limitations 
prohibited verifying that all oligodendrocytes expressed the mutant SOD1 so it is difficult to 
draw a strong conclusion from these studies.  
Interest in the oligodendrocyte progenitor cells, also called NG2+ cells, has risen in the ALS 
field due to recent reports of their aberrant proliferation in rodent models. These NG2+ cells 
are found widely throughout the CNS and are mitotically active, especially in areas of injury 
or neuronal degeneration. Although the specific functions of these cells is still under 
investigation, these NG2+ cells can divide and differentiate into myelinating 
oligodendrocytes, but not into astrocytes or neurons in vivo (Kang et al., 2010). Several 
studies have reported a dramatic (20-fold) increase in proliferation of NG2+ cells over the 
course of disease in ALS mouse models, with NG2+ cells contributing to over half of the 
total dividing cell population in the spinal cord of symptomatic mice (Kang et al., 2010; 
Lepore et al., 2008a; Magnus et al., 2008). Differentiation of these NG2+ cells into 
oligodendrocytes is also enhanced in mutant SOD1 mice compared to wild-type mice for 
reasons still unknown (Kang et al., 2010). It has been proposed that oligodendrocytes 
undergo degeneration in response to motor neuron loss and the NG2+ cell proliferation and 
differentiation is an attempt to restore these lost oligodendrocytes. However, it will be 
crucial to dissect what effects are primary and secondary to motor neuron loss and what 
role, if any, NG2+ cells play in disease course. Studies investigating how mutant SOD1 
influences normal NG2+ cell behavior are warranted, including analysis of whether mutant 
SOD1 NG2+ cells share a similar non-cell autonomous toxicity as astrocytes and microglia.  
2.4 Glial cell involvement in TDP43/FUS ALS? 
A defining pathological feature in post-mortem ALS tissue is ubiquitin-positive inclusions 
within neurons and glia in the spinal cord, brainstem, and motor cortex. In patients with 
SOD1 mutations, these inclusions contain misfolded SOD1 protein (Bruijn et al., 1998). 
However, in ALS patients lacking SOD1 mutations, these inclusions contain one of two 
RNA/DNA binding proteins: TAR DNA-binding protein 43 (TDP43) or fused in sarcoma 
protein (FUS) (Kwiatkowski et al., 2009; Mackenzie et al., 2007; Neumann et al., 2006; Vance 
et al., 2009). Genetic analyses have also revealed disease-linked mutations in both TDP43 
and FUS in subsets of familial and few sporadic ALS patients, adding to evidence that these 
proteins are involved in ALS pathogenesis (Kabashi et al., 2008; Kwiatkowski et al., 2009; 
Sreedharan et al., 2008; Vance et al., 2009). However, a major question that remains is 
whether glial cells play an active role in ALS disease caused by TDP43 or FUS mutations.  
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Animal models are in development to better understand pathological disease mechanisms 
in TDP43 and FUS ALS. Thus far, a number of rodent models have been described for 
TDP43 ALS and these models vary in the TDP43 mutations expressed and the promoter 
used to drive expression (Cohen et al., 2011). The phenotypes observed in these models have 
been somewhat perplexing due to the difficulties in dissecting the effects of human TDP43 
protein overexpression from mutant-specific effects. Nonetheless, a common theme in these 
animals is neurodegeneration accompanied by neuronal cytoplasmic aggregates in affected 
regions. None of the models to this point have reported glial pathology other than an 
increase in gliosis at sites of neuronal injury which may be secondary to neuronal death. 
Likewise, in the first reported rodent model for FUS ALS, astrogliosis and microgliosis were 
the only noted glial-specific pathologies (Huang et al., 2011). In contrast, TDP43- and FUS- 
positive inclusions are found in glial cells in post-mortem ALS spinal cord and it is difficult 
to know whether these inclusions were overlooked in the early animal models or whether 
they represent a discrepancy between human ALS and rodent models (Mackenzie et al., 
2010).  Careful dissection of the effects of mutant TDP43 and FUS in astrocytes, microglia, 
and oligodendrocytes (as well as NG2+ progenitors) will be essential to determine whether 
the non-cell autonomous disease nature extensively noted in SOD1 ALS is also recapitulated 
in TDP43- and FUS-mediated ALS.  
3. ALS disease modeling using glial cells 
Transgenic mouse models have played a key role in elucidating how glial cells affect the 
disease course of ALS.  There are obvious advantages to in vivo models; however, it is 
often difficult to dissect the specific contributions of various cell populations from other 
influences in the CNS milieu. In parallel with these in vivo studies, several groups have 
established novel in vitro ALS models that recapitulate the glial-mediated motor neuron 
toxicity observed in transgenic ALS mouse models. Most of these in vitro models involve 
a co-culture where wildtype motor neurons are co-cultured with mutant SOD1 glia or 
wild-type glia. The goal is to determine the direct effects of diseased glia on motor 
neurons. Furthermore, in vitro models allow for the study of human cells derived from 
ALS patients. Most studies striving to correlate work from the ALS rodent model with 
human ALS rely on post-mortem tissue analysis, which makes it difficult to sort out 
primary contributors to motor neuron loss from secondary effects caused by 
neurodegeneration and the inflammatory response in the endstage spinal cord.  These in 
vitro models provide a unique avenue to study human ALS in real-time and evaluate 
therapeutics and disease mechanisms.  
3.1 Motor neuron-glial cell co-cultures recapitulate glial-derived motor neuron 
damage  
Transgenic models have shown that removing the mutant SOD1 gene in microglia reduces 
motor neuron loss in the mutant SOD1 mouse model (Beers et al., 2006; Boillee et al., 2006b). 
Similar work has recapitulated this motor neuron loss using primary microglia isolated from 
mutant SOD1 mice in a co-culture with motor neurons. These studies have demonstrated 
that mutant SOD1-expressing microglia are more neurotoxic compared to wild-type 
microglia (Beers et al., 2006; Weydt et al., 2004; Xiao et al., 2007) which is not surprising 
given that mutant SOD1 microglia release an array of toxic inflammatory factors including 
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nitric oxide, reactive oxygen species, TNF-┙, and IL-1 (Almer et al., 1999; Henkel et al., 2009; 
Hensley et al., 2003; Nguyen et al., 2001; Sasaki et al., 2000; Weydt et al., 2004; Xiao et al., 
2007).  Motor neurons co-cultured with mutant SOD1-expressing microglia show a 
reduction in the number and length of neurites and reduced survival in the co-culture 
paradigm (Xiao et al., 2007). In addition, microglia treated with extracellular mutant SOD1 
protein become inflamed and damaging to motor neurons in co-culture (Urushitani et al., 
2006; Zhao et al., 2010). The extracellular mutant SOD1 only caused motor neuron death 
when microglia were added into the culture, indicating the motor neuron damage was 
directly initiated by microglia (Zhao et al., 2010). These in vitro systems could provide a 
platform for testing therapeutics that could potentially block neurotoxic microglia. For 
example, in vitro treatment with IL-4 caused mutant SOD1-expressing microglia to 
differentiate from an “M1” proinflammatory phenotype to an “M2” neuroprotective 
phenotype and improved motor neuron survival in co-culture (Zhao et al., 2006). It remains 
to be determined whether IL-4 will have the same effect when delivered to microglia in vivo.  
More efforts have focused on studying aberrant astrocyte function in mutant SOD1-based in 
vitro ALS models. Several studies have demonstrated that astrocytes isolated from mutant 
SOD1 mice (Di Giorgio et al., 2007; Nagai et al., 2007) as well as astrocytes derived from 
neural stem cells from these mice (Dodge et al., 2008) are toxic to wild-type motor neurons 
in co-culture. In these studies, primary motor neurons as well as motor neurons derived 
from mouse embryonic stem cells were shown to die more quickly in vitro when cultured on 
top of SOD1 G93A astrocytes compared to wild-type astrocytes. It has also been recently 
shown that human motor neurons differentiated from embryonic stem cells are susceptible 
to the same astrocytes isolated from the SOD1 G93A mouse model (Di Giorgio et al., 2008). 
Furthermore, human motor neurons derived from embryonic stem cells die in the presence 
of human fetal primary astrocytes overexpressing mutant SOD1 by lentivirus (Marchetto et 
al., 2008). These in vitro models support that mutant SOD1-expressing astrocytes are toxic to 
motor neurons regardless of the species and provide a way to study familial ALS utilizing 
human cells. While these results have been exciting, no consistent pathway has been 
implicated in these in vitro studies for causing motor neuron death; however, one common 
finding is that the toxicity is transferred through the media, suggesting a secreted factor may 
be responsible.  Future studies will hopefully identify the specific factor(s) involved in this 
toxicity. 
3.2 ALS disease modeling using human-derived cells 
Development of in vitro ALS models provides another tool to investigate disease 
mechanisms and test therapeutics for ALS. Unfortunately, there has been a disconnect in the 
translation of drugs from rodent models of ALS to human clinical trials. While various 
drugs have shown promise in rodent models, there continues to be disappointment in 
clinical trials which may be a result of various factors including poor preclinical testing 
regimen, ineffective clinical design and delivery, or use of an animal model that does not 
accurately reflect human disease (Benatar, 2007).  Indeed, most ALS models currently used 
for therapeutic testing are based on fALS caused by SOD1 mutations. Since fALS only 
accounts for 5-10% of ALS cases and SOD1 mutations are only present in 20% of these fALS 
patients, rodent ALS models may only represent 2% of all ALS cases. Thus, efforts have 
been focused on developing in vitro cell based models for sALS, representing the majority of 
the patient population.  Human ALS-based in vitro models could be a helpful tool to identify 
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drugs which modulate glial activity and be utilized as a complement to the mutant SOD1 
mouse model to select more effective drugs for further clinical development.  
Several methods can be employed to derive patient-specific glia for in vitro study. While it is 
difficult to isolate primary astrocytes or microglia from post-mortem tissue in large enough 
quantities, neural progenitor cells can be harvested from post-mortem brain and spinal cord 
tissue (Palmer et al., 2001). These human neural progenitor cells can be continuously 
expanded in vitro and differentiated into neurons, astrocytes, or oligodendrocytes for study. 
Recently, it has been shown that isolation of neural progenitor cells from post-mortem ALS 
spinal cord is feasible and astrocytes can be generated from these progenitors (Haidet-
Phillips et al., 2011). Astrocytes derived from a fALS patient harboring a SOD1 mutation 
were co-cultured with wild-type motor neurons and a 50% increase in neuronal cell death 
was observed compared to co-culture with astrocytes from non-ALS controls, recapitulating 
evidence from the mutant SOD1 mouse model. However, it was also shown for the first time 
that astrocytes derived from sALS patients, which represent the majority of ALS patients, 
were similarly toxic to motor neurons in co-culture. The motor neuron death was shown to 
be triggered by conditioned astrocyte media, suggesting toxic secreted factors are 
responsible for motor neuron damage as seen in the mouse astrocyte co-culture studies. 
These results indicate a shared mechanism leading to motor neuron death between fALS 
and sALS through astrocyte-mediated toxicity and suggest therapies directed at astrocytes 
may be beneficial for both ALS populations. 
In addition to neural progenitor cells, there are other stem cell sources which can be 
potentially used to derive patient-specific glial cells or motor neurons in vitro. With the 
development of induced pluripotent stem cell (iPSC) technology, many groups are also 
striving to create populations of neurons and astrocytes from iPSCs for disease modeling. 
iPSCs are pluripotent stem cells generated by reprogramming somatic cells through forced 
expression of specific pluripotency transcription factors. Like embryonic stem cells, iPSCs 
are characterized by an immense proliferative capacity and the ability to differentiate into all 
three germ lineages (endoderm, ectoderm, and mesoderm) which can eventually give rise to 
all tissues of the body (Yamanaka & Blau, 2010).  A variety of different cell types have now 
been reprogrammed into iPSCs including both mouse and human somatic cells (Okita et al., 
2007; Park et al., 2008; Takahashi et al., 2007; Takahashi & Yamanaka, 2006; Wernig et al., 
2007; Yu et al., 2007). Importantly, protocols have also been developed for the differentiation 
of motor neurons, astrocytes, and oligodendrocytes from human iPSCs, which allow for in 
vitro ALS disease modeling (Czepiel et al., 2011; Dimos et al., 2008; Krencik et al., 2011; Liu 
et al., 2011).   
Several groups have reprogrammed human fibroblasts from ALS patients into iPSCs and 
successfully differentiated motor neurons from these iPSCs (Boulting et al., 2011; Dimos et 
al., 2008). However, the major hurdle thus far has been demonstration of a disease-related 
phenotype in the iPSC-derived motor neurons. It may be necessary to either stress the iPSC-
derived motor neurons or co-culture with astrocytes also generated from ALS patient iPSCs 
in order to observe motor neuron damage. Still, it may be difficult to reproduce a relevant in 
vitro phenotype when working with diseases that are complex and likely multifactorial such 
as sALS. Another question posed by these experiments is whether or not reprogramming a 
cell and concordant epigenetic remodeling causes the loss of the ALS “signature”. If 
sporadic ALS is triggered in part by epigenetic modifications, reprogramming may 
eliminate this epigenetic profile leaving essentially a “wild-type” cell. Therefore, 
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comparisons between cells derived from ALS post-mortem tissues (not reprogrammed) and 
ALS-derived iPSCs may be crucial for dissecting these issues.   
Although still in development, these in vitro-based ALS models provide a valuable platform 
for further mechanistic and therapeutic studies. Many of these models employ the use of 
Hb9-GFP reporter cell lines to generate motor neurons allowing for easy visualization of 
motor neuron survival over time in co-culture. With the reported ability to track motor 
neuron survival in real-time in a 96 well plate format (Haidet-Phillips et al., 2011), the 
development of high-throughput screens is foreseeable. Therapeutic compounds could be 
quickly screened for motor neuron protection against glial-cell mediated toxicity in this 
format. Additionally, one could envision genetic screens for modifiers of glial-cell derived 
motor neuron damage, leading to new therapeutic approaches or insights into disease 
mechanisms. Since there are currently no models for sALS, these in vitro-based systems 
utilizing either post-mortem neural progenitor or iPS-derived cells could provide a much 
needed novel platform for drug discovery. Although promising, some limitations do exist 
for in vitro modeling systems. For example, the time course for modeling motor neuron 
disease in vitro is short (days to weeks) whereas ALS is a late onset disorder which usually 
does not develop until 40-60 years of age. Additionally, the heterogeneity of ALS cases may 
pose another challenge, requiring a large number of both disease and control samples in 
order to identify relevant disease-related changes in vitro. Lastly, although in vitro modeling 
allows for dissection of cell-specific phenotypes, it will be important to evaluate any noticed 
changes in an in vivo context where many cell types interact and can influence disease.  
4. Therapeutic advances to target glial cells in ALS 
In recent years, much emphasis has been placed on the role of glial cells in mutant SOD1 
mouse models and some of these findings have been recapitulated in vitro using human ALS 
patient-derived cells. Thus, many groups are devoting significant efforts to development of 
therapies directed at modulating glial cell activity. Indeed, glial cells have been suggested to 
affect both disease onset and progression in ALS mouse models.  Since the majority of ALS 
patients are only diagnosed well after the onset of disease, therapies targeting disease 
progression by modification of glial cells may be beneficial in slowing symptomatic disease 
processes.  
4.1 Therapeutic agents to target astrocytes and microglia 
Currently, there is only one US Food and Drug Administration (FDA)-approved drug for 
the treatment of ALS and its therapeutic effects are hypothesized to derive from 
counteracting aberrant glutamate metabolism.  Riluzole is an inhibitor of presynaptic 
glutamate release which may offset excitotoxicity seen in ALS.  Riluzole has been confirmed 
to alter ALS disease survival in four independent clinical trials providing strong support for 
its therapeutic benefits (Miller et al., 2007). Unfortunately, riluzole only extends lifespan in 
ALS patients by an average of 3 months so efforts have focused on identifying other 
compounds which can counteract glutamate excitotoxicity. A variety of other drugs 
targeting glutamatergic pathways (talampanel, memantine, topiramate, lamotrigine, 
gabapentin, ONO-2506) have been evaluated in ALS patients, but the results have not 
suggested a benefit on disease course (Cudkowicz et al., 2003; de Carvalho et al., 2010; 
Miller et al., 2001; Ryberg et al., 2003; Zinman & Cudkowicz, 2011).  
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To identify new medications which may modulate glutamatergic pathways, an in vitro 
screening of over 1000 compounds already approved by the US Food and Drug 
Administration was completed (Rothstein et al., 2005). From this screen, ┚-lactam antibiotics 
were found to upregulate expression of the glutamate transporter, GLT1, and one of these 
antibiotics, ceftriaxone, was shown to significantly delay disease progression in the SOD1 
G93A mouse model. Clinical trials testing intravenous ceftriaxone administration in ALS 
patients have already passed safety and tolerability stages and are currently in the final 
phase III of evaluation (Zinman & Cudkowicz, 2011).  
In contrast to specific targeting of glutamatergic pathways, a variety of anti-inflammatory 
agents have been tested with hopes to combat the extensive glial reaction observed in ALS 
patient brain and spinal cord.  Prostaglandins are mediators of the inflammatory response 
that can be released in response to immune stimuli and production of prostaglandins is 
increased in the spinal cord of ALS patients (Kondo et al., 2002). Prostaglandin stimulation 
can be reduced by inhibiting cyclooxygenase 2 (COX2), an inducible enzyme involved in the 
synthesis of prostaglandins. Treatment of SOD1 G93A mice with COX2 inhibitors lowers 
prostaglandin levels and prolongs survival in these mice (Drachman et al., 2002; Klivenyi et 
al., 2004; Pompl et al., 2003). Unfortunately, the COX2 inhibitor, celecoxib, was ineffective at 
increasing survival in a clinical trial of ALS patients (Cudkowicz et al., 2006). However, 
prostaglandin E2 levels in the CSF of these patients was unaltered by celecoxib therapy 
indicating the dose may have been too low to reach therapeutic levels in the CNS (Aggarwal 
& Cudkowicz, 2008).  
Additional efforts to modulate the immune response in ALS have also been unsuccessful. 
The anti-microbial drug, minocycline, was shown to inhibit microglial activation and 
lengthen survival in mouse models of ALS (Kriz et al., 2002; Van Den Bosch et al., 2002; 
Zhu et al., 2002). Nonetheless, in a multicenter, randomized, phase III clinical trial of 
over 400 ALS patients, minocycline did not increase survival and in fact, was shown to 
worsen disease course in these patients (Gordon et al., 2007). The apparent divergence in 
results between preclinical animal studies and the clinical trial may have been due to the 
timing of minocycline treatment.  When tested in animal models, minocycline was 
administered prior to symptomatic disease onset, whereas patients received the drug 
only after clinical onset of ALS. Indeed, a recent study showed that treatment of SOD1 
G93A mice with minocycline administered after disease onset conferred no survival 
benefit and highlights the importance of a clinically-relevant testing regimen in ALS 
mouse studies (Keller et al., 2011). Compounds which modify neuroinflammation 
already present in the spinal cord, in contrast to preventing inflammation, may be more 
successful in the clinical setting.  
4.2 Stem cell therapies for ALS 
Because mounting data indicate that pathogenic glial cells actively contribute to motor 
neuron loss in ALS, one developing strategy is to replace the diseased glia with healthy cells 
which may alter the endogenous spinal cord environment and promote motor neuron 
survival. Transplantation of terminally differentiated glia to the CNS may pose technical 
difficulties since these cells are typically mature with limited proliferative and migratory 
capacity. Therefore, exploration of stem cells as a source for glial replacement has been 
sought after by many groups.  
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Mutant SOD1-expressing microglia are key drivers of disease progression in mouse models 
of fALS. Since microglia are derived from the hematopoietic lineage, hematopoietic stem 
cells are one possible source for microglial cell replacement. When SOD1 mice lacking 
microglia are given bone marrow transplants from wild-type mice, the microglial cell 
population is reconstituted with healthy microglia and survival is prolonged (Beers et al., 
2006). In translating this line of investigation to ALS patients, allogeneic peripheral blood 
hematopoietic stem cells were transplanted into ALS patients following full body irradiation 
(Appel et al., 2008). Although transplanted cells remarkably migrated to sites of motor 
neuron injury, no clinical change in disease was observed. It is possible that either the 
transplanted cells did not differentiate into microglia or that a large proportion of 
endogenous microglia survived post-irradiation which outnumbered healthy, transplanted 
stem cells. Trials are ongoing to similarly test intraparenchymal transplantation of 
hematopoietic stem cells to ALS patients (Deda et al., 2009), but results may be difficult to 
interpret based on the use of autologous (and potentially diseased) stem cells as a source 
instead of allogeneic (from a matched donor) derived stem cells. Further studies are needed 
in ALS rodent models to determine the optimal cell type, number, and delivery method for 
transplantation to establish a critical proof-of-principle for these paradigms. 
Further efforts have focused on replacement of diseased astrocytes using various cell 
sources and delivery approaches. In contrast to microglia, astrocytes are derived from the 
neural lineage and can be differentiated from several stem cell sources including both glial-
restricted precursors as well as neural stem and progenitor cells. Thus far, transplantation of 
neural progenitor cells to rodent ALS models has resulted in either a lack of differentiation 
in vivo (Klein et al., 2005; Suzuki et al., 2007) or differentiation to mostly neurons after neural 
stem cell transplantation, but not to astrocytes (Xu et al., 2009; Xu et al., 2011).  
In contrast, glial-restricted precursors are lineage-restricted and can only become astrocytes 
or oligodendrocytes. Transplantation of glial-restricted precursors to the cervical spinal cord 
of SOD1 G93A rats led to extensive differentiation of grafted cells into astrocytes (>85% of 
transplanted cells) which reduced significant motor neuron loss (Lepore et al., 2008b). The 
graft-derived astrocytes expressed increased levels of GLT1 in comparison to endogenous 
diseased astrocytes, which likely played a major role in protecting motor neurons. 
Importantly, rats receiving transplants also survived longer and showed preserved forelimb 
grip strength and respiratory function, attributable to the focal delivery of glial-restricted 
precursor cells to the cervical region of the spinal cord. This work provides a proof-of-
principle for astrocyte replacement in ALS and sets the stage for future clinical trials testing 
transplantation of human glial-restricted precursors in ALS patients. Questions still remain 
as to whether human glial-restricted precursors will survive and differentiate after 
transplantation into humans and which spinal cord regions are most practical for targeting 
in ALS patients.  
With the advancement of stem cell technology, astrocytes as well as neural progenitors (and 
possibly glial-restricted precursors) can now be derived from human iPS cells. This novel 
stem cell source provides another option for glial-cell replacement therapies since iPS cells 
have immense expansive abilities in vitro. A major potential advantage to iPS cells is that 
these cells can be derived directly from a living patient. In theory, use of autologous iPS cells 
for transplantation therapies may lessen worries of graft rejection and obviate the need for 
continued immunosuppressive therapy. However, one study testing this paradigm 
documented rejection of mouse iPS cells after transplantation to an autologous recipient, 
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cautioning that transplantation of these cells may be more complex than originally thought 
(Zhao et al., 2011).  Another issue is whether stem cells derived from ALS patients carry the 
disease phenotype. If so, any cells differentiated from the patient iPS cells may not provide 
the desired therapeutic benefit. In cases where there exists a disease-associated mutation 
such as SOD1, ex-vivo genetic correction of the mutation through homologous 
recombination, viral vectors, or zinc finger technology may be possible (Amabile & 
Meissner, 2009). However, most ALS patients have no identified genetic mutation 
responsible for the disease. Additionally, there remain many unresolved challenges with iPS 
cell therapy such as obtaining efficient differentiation of the iPS cells to the desired cell 
population, purifying a safe and non-tumorgenic population for transplantation, and 
optimizing delivery methods for transplantation of the iPS-derived cells back to the patient. 
In addition to benefits derived from replacing diseased glia, transplanted populations of 
stem cells may also be used to deliver therapeutics to the brain and spinal cord.  Stem cells 
can be genetically modified in vitro by transduction with viral vectors which can integrate 
into the genome and stably express therapeutic genes long-term.  Since many therapeutic 
proteins have short half-lives after direct injection, genetically modified stem cells 
transplanted to the brain or spinal cord would allow for continuous production of the 
desired protein at the site of neurodegeneration, serving as “therapeutic pumps” in vivo. For 
example, human neural progenitor cells transduced with a lentivirus expressing glial-
derived neurotrophic factor (GDNF) and transplanted to the ALS rat spinal cord can 
produce GDNF in vivo and protect motor neurons (Klein et al., 2005; Suzuki et al., 2007). One 
could envision using stem cells to deliver not only neuroprotective factors, but also 
therapies to modulate the glial environment such as anti-inflammatory proteins or anti-
glutamatergic agents. 
4.3 Gene-targeted therapies for ALS 
The mechanisms leading to motor neuron death in ALS are still unclear; however, it is 
generally agreed in the field that in cases of SOD1 fALS, the mutant SOD1 protein harbors a 
toxic gain-of-function and reduction of mutant SOD1 is likely to be beneficial in these patients. 
Additionally, several studies have implicated a pathogenic role for wild-type SOD1 in cases of 
sALS (Bosco et al., 2010; Gruzman et al., 2007), including a potential role in glial cells (Haidet-
Phillips et al., 2011). Therefore, therapies aimed at reducing SOD1 levels may potentially be 
applicable for not only SOD1 fALS patients, but for other ALS patient populations as well.  
A variety of approaches have been attempted to reduce SOD1 levels in rodent models of ALS.  
RNA interference (RNAi) is a post-transcriptional gene-silencing mechanism initiated by small 
interfering RNAs (siRNA) which are double-stranded pieces of RNA 21-23 nucleotides in 
length (Sah & Aronin, 2011). Within the cytoplasm, the siRNA gets recognized and directed to 
the RNA-induced silencing complex.  The silencing complex then uses the sequence-specific 
information on the siRNA to initiate degradation of endogenous complementary mRNA 
sequences, leading to subsequent gene silencing.  Targeted siRNA can be exogenously 
delivered to a cell although naked siRNA is instable with a relatively short half life (Sah & 
Aronin, 2011). Alternatively, viral vectors can be used to continuously transcribe RNA 
containing short complementary sequences (Miller et al., 2008). These complementary 
sequences can bind, leading to duplex hairpin formation (short hairpin RNA or shRNA). Once 
transcribed, the shRNA gets recognized by the cellular machinery and cleaved by the Dicer 
enzyme to produce short, double-stranded siRNA sequences.  
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Sequences of siRNA targeted against SOD1 mRNA have been designed to reduce levels of 
the mutant SOD1 protein. Similar to many small molecule therapies, siRNA does not cross 
the blood-brain-barrier, creating challenges for delivery to the CNS (Sah & Aronin, 2011). 
Viral-mediated delivery of SOD1 shRNA has been attempted in rodent models of ALS with 
successful knockdown of SOD1 levels by both lentivirus and adeno-associated virus (AAV) 
(Miller et al., 2005; Ralph et al., 2005; Towne et al., 2011). However, these studies have 
targeted only motor neurons, transduced after retrograde transport from muscles injected 
with the virus. These strategies were unsuccessful in slowing disease progression, most 
likely due to the fact that motor neurons were solely targeted, although glial cells play a 
significant role in the disease process. 
Other approaches have strived to target both motor neurons and glial cells with SOD1 
shRNA. Intraparenchymal injection to the lumbar spinal cord of a lentivirus encoding SOD1 
shRNA was shown to reduce SOD1 levels and retard disease onset and progression in the 
SOD1 G93A mouse (Raoul et al., 2005). Yet, the vast anatomical distribution of diseased cells 
throughout the motor cortex, brain stem and spinal cord pose a hurdle for direct injection of 
viral therapy with limited diffusive capacity. A novel version of AAV, AAV serotype 9, has 
recently shown potential for extensive targeting of CNS tissues (Foust et al., 2009). In this 
study, AAV9 was able to cross the blood-brain-barrier after vascular delivery and transduce 
over 60% of astrocytes in the brain and spinal cord. Additional evaluation in non-human 
primates verified that AAV9 is capable of efficiently targeting both motor neurons and glia 
in the brain and spinal cord after vascular delivery to a large species (Bevan et al., 2011). Use 
of this virus to deliver SOD1 shRNA is conceivable, although steps may be needed to target 
viral expression away from peripheral organs and only to CNS tissues.  
Instead of using a viral vector to deliver shRNA sequences, others have sought to create 
more stable siRNA for direct delivery through chemically modifying the siRNA (Wang et 
al., 2008). Intrathecal infusion of chemically-modified SOD1 siRNA using an osmotic pump 
generated a 15% knockdown in SOD1 protein levels and a modest therapeutic effect in the 
SOD1 G93A mice. One potential advantage to infusion of naked, stabilized siRNA over viral 
delivery is the ability to halt the treatment at any time following adverse effects. Therefore, 
this type of RNAi therapy seems promising at least for treatment of ALS patients with SOD1 
mutations.  
A similar approach to RNAi therapy involves the use of antisense oligonucleotides to enact 
post-transcriptional gene silencing (Sah & Aronin, 2011). Antisense oligonucleotides are 
short (15-25 nucleotides) single stranded pieces of synthetic DNA which can bind to 
complementary mRNA sequences in the cytoplasm. Once bound, these DNA-mRNA 
complexes are targeted for degradation by the enzyme RNase H. Additionally, translation of 
mRNA bound by antisense oligonucleotides can be physically blocked, leading to further 
gene silencing for targeted mRNA sequences. Antisense oligonucleotides are generally more 
stable than naked siRNA with a half life of 2-6 weeks after delivery to the mouse and 
monkey CNS (Sah & Aronin, 2011). Like siRNA, antisense oligonucleotides can be absorbed 
by both neurons and glia to execute gene silencing. Sequence specific targeting of antisense 
oligonucleotides to SOD1 mRNA has been attainable, with a 50% reduction in SOD1 protein 
levels in the brain and spinal cord of SOD1 G93A rats infused for 28 days with antisense 
oligonucleotides into the right ventricle (Smith et al., 2006). The rats treated with SOD1 
antisense oligonucleotides showed a slowed disease progression and this same SOD1 
antisense oligonucleotide was demonstrated to lower SOD1 levels in fibroblasts isolated 
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from an ALS patient. A phase I clinical trial has been initiated in fALS patients with SOD1 
mutations testing intrathecal infusion of this same antisense oligonucleotide against SOD1. 
This dose-escalation trial will evaluate safety, tolerability, and pharmacokinetics in patients 
treated with antisense oligonucleotide infusion for 12 hours. If proven safe, this strategy 
holds considerable promise to treat SOD1 fALS patients.  
While a great deal of progress has been made in the development of anti-SOD1 therapies, 
additional work needs to be focused on advancing novel treatments for non-SOD1 ALS 
patient populations. As additional genetic mutations are linked to ALS, these genes might 
present new targets for gene-based therapeutic approaches. However, in the case of TDP43 
and FUS mutations, a great deal of basic research is still required to evaluate whether a loss-
of-function or gain-of-function mechanism is responsible for disease caused by these 
mutations and whether glial cells are also a target in these cases. Until these crucial 
questions are answered, it will be difficult to develop RNAi or gene therapy treatments for 
these patients. Efforts to reach a broad ALS patient population may benefit most from the 
design of therapies which interfere with downstream mechanisms prevalent in most 
patients, such as glial-mediated glutamate excitotoxicity or neuroinflammation.  Many of 
the siRNA and antisense oligonucleotide approaches can be amenable to inhibit potentially 
damaging genes involved in these glial responses. Additionally, viral vectors have been 
developed that can deliver gene therapies to glial cells in the CNS, allowing for potential 
immune modulation. With increasingly innovative developments in RNAi and gene 
therapy, the door is open for novel gene-based therapies to alter the ALS disease process.  
5. Conclusion 
The field of ALS research has progressed significantly in recent years with the identification 
of glial cells as an active contributor to the disease process. Specifically, astrocytes and 
microglia have been recognized as glial cell types which undeniably influence survival in 
rodent models of ALS. Efforts are underway to test therapies aimed at modifying the glial 
cell population in hopes of slowing ALS disease progression and extending patient survival.  
While rodent models of ALS have been key in revealing glial cells as a disease contributor in 
SOD1 fALS, it still remains to be determined to what extent glial cells are involved in 
disease processes in other patient populations. New genes have been recently linked ALS 
including TDP43 and FUS, suggesting a possible role for RNA metabolism in disease 
pathogenesis. Creation of both rodent and in vitro models mimicking these forms of ALS is 
underway and will hopefully reveal whether glial cells are also a target in patients 
harboring these mutations. 
Although glial cell targets have been identified, much work remains to elucidate the 
mechanisms behind their neural toxicity. Several groups have been able to model the glial-
motor neuron interface in vitro using unique stem-cell based models to study the effects of 
diseased glia on motor neurons. While these studies have yet to identify relevant 
mechanisms involved in glial-mediated toxicity, in vitro models present the opportunity to 
study human patient-derived glial cells from both fALS and sALS patients.  With the 
development of iPSC technology, there exists potential to study patient-specific glial cells 
and evaluate therapies in a high-throughput fashion.  
Discovery of mechanisms involved in glial pathogenicity will likely lead to the development 
of promising therapeutic interventions.  Detection of additional pathways of importance 
will hopefully shed light on new compounds which may be capable of targeting glial-
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mediated motor neuron damage. Furthermore, stem cell and gene-based therapies have 
reached evaluation in clinical trials, creating excitement and optimism in the field. As new 
knowledge of disease mechanisms arises, there is great hope for novel interventions to 
target glial cells and significantly change the ALS disease course.  
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